Research & Discovery

The researchers at the startup have developed a microarray test to predict patients' response to chemotherapy based on chromatin accessibility.

The study found certain patients did not benefit from lower doses of radiation therapy, suggesting the need for molecular selection.

Datavant will anonymize lung cancer records from the Biodesix biobank and add real-world data to aid researchers and biopharma companies.